Please type a plus sign (+) inside this box → +			Patent and Trader	nark Office: U.S	DEPARTMENT OF COMMER	RCE
UTILITY	Attorney Docke	t No.	AG0073-01-US			
PATENT APPLICATION	First Inventor		Steven Lee Be	ender		_
TRANSMITTAL	Title		AMIDE COMPOU COMPOSITIONS METHODS FOR 1	FOR INHIBITIN	RMACEUTICAL G PROTEIN KINASES, AND	PT
(Only for new nonapplications under 37C.F.R. §1.53(b))	Express Mail L	abel No.	EV341079272U	IS		v
APPLICATION ELEMENTS		ADI	DRESS TO:	Mall Stop P	atent Applications ner for Patents	-
See MPEP chapter 600 concerning utility patent application	contents.			Box 1450	VA 22313-1450	1
Fee Transmittal Form (e.g., PTO/SB/I)  Globent an eriginals, and a deplicate for the process  Applicant claims small entity status See 37 CFR 1:27  Specification (Total Pages (preferred arrangement set forth below)  Descriptive title of the Invention  Cross References to Related Applica  Statement Reparating Fod sponsyers.	ng)  [212 ]  Itions	(if a	computer Prog electide and/or An epplicable, all nece a. Compute.	ram (Appendi: nino Acid Sequ	ence Submission  Copy (CRF)  ing on:	
Reference to sequence listing, a table			ii. Paper			
or a computer program listing append	dix				dentity of above copies	
Background of the Invention			ACCOMPANY	ING APPLI	CATION PARTS	_
<ul> <li>Brief Summary of the Invention</li> <li>Brief Description of the Drawings (if and Description)</li> <li>Claim(s)</li> </ul>	filed)	9.	Assignment Pa 37 CFR 3.73(b) (when there is	Statement	neet & document(s)) Power of Attome	y
<ul> <li>Abstract of the Disclosure</li> </ul>		ы. Г	1		nt (if applicable)	
4. Drawing(s) (35 U.S.C. 113) [Total sheets		12.	Information Dis Statement (ID:	sclosure	Copies of IDS Citations	
5. Oath or Declaration [Total pages	4 ]	13. 🛚	Preliminary Ar	nendment		
a. Newly executed (original or cop		14.	Return Receip			
b. Copy from a prior application (37 CF (for continuation/divisional with Box	18 completed)	15.	Certified Copy	of Priority Do	*	
<ul> <li>i. DELETION OF INVE Signed statement attached deletin named in the prior application, see 1.63(d)(2) and 1.33(b).</li> </ul>	g inventor(s)	16.	Nonpublication	Request und	er 35 U.S.C. 122 ttach form PTO/SB/35	
6 Application Data Sheet. See 37 CFR 1.	76	17.	Other:			
18. If a CONTINUING APPLICATION, check appr	opriate box, and su	_		low and in a prei	iminary amendment.	_
or in an Application Data Sheet under 37CFR 1.76.						
Continuation Divisional	Continuation				No: <u>09/ 764,306</u>	
For CONTINUATION OR DIVISIONAL APPS only. The er	er <u>Kahsay Habte</u>	the prior ap	plication, from wh	rt Unit: 1624	eclaration is supplied under	_
Box 5b is considered a part of the disclosure of the acc The incorporation can only be relied upon when a porti	ompanying contin	uation or di	visional applicatio	n and is hereby	Incorporated by reference.	
18.			E ADDRESS	писа прриса	on parts	
Customer Number or Bar Code Label (Insert Cus	tomer No. or Atta		label here) or	Correspond	ence address below	
Name						_
Address						_
City	State			Zip Code		
	elephone			Fax		_
NAME (Print/type) Joseph F. Fjeldy	- L. J.	Registration	on No. (Attorney/		9,340	ı
Signature VIII +.	year		Date		uly 17, 2003	i
<i>    </i>	´ //					

PTC/SB\*17(01/03)
PTC/SB

FEE TRANSMITTAL  for FY 2003    Filing Date	Fee Paid						
Applicant claims small status. See 37 CFR 1.27							
Examiner Name							
Examiner Name							
Attorney Docket No.							
Table   Manage   Table   Money Order   Gly918.00   Money Order   Gl							
Check   Credit Card   Money Order   Other   None   Carde							
Check   Credit Card   Money Order   Other   None   Carde							
Deposit   Account   Number   Surpharmaceuticals, Inc.     1051   130   2051   55   Surcharge—late feer or oath   1052   1053   1							
Deposit Account   Agouron Pharmaceuticals, Inc.   1051 130 2051 95 Surcharge—late fee or oath Account Name   Agouron Pharmaceuticals, Inc.   1051 130 2051 95 Surcharge—late fee or oath Name   Agouron Pharmaceuticals, Inc.   1051 130 2051 95 Surcharge—late fee or oath Name   Account Name   1052 1052 205 25 Surcharge—late filing fee or ocver sheet   1053 130 105							
Deposite   Account   Agouron Pharmaceuticals, Inc.   1061   130   2061   65   Surcharge - late fee or oath	Paid						
Account Name  Agouron Pharmaceuticals, Inc.  The Commissioner is authorized to: (check all that apph)  Charge any additional feel) during the pendency of this application  Charge Pacel indicated below. ■ Commissioner is authorized to: (check all that apph)  Charge any additional feel) during the pendency of this application  Charge Pacel indicated below. except for the filling fee to the above- identified deposit account.  1802 50 2052 1812 2,529 Filling a diquest for revamination  1812 2,520 1812 2,529 Filling a diquest for revamination  1804 920* 1804 920* Requesting publication of SIPI partic  1805 1,840* 1805 1,840* Requesting publication of SIPI partic  1.883IC FILING FEE  Large Entity  Small Entity  Small Entity  Small Entity  Small Entity  Small Entity  Small Entity  1252 410 2252 205 Extension for reply within first morth  1253 130 2253 455 Extension for reply within fres morth  1254 1,450 2254 725 Extension for reply within for morth  1001 750 2001 375 Usity filing fee  750 1255 1,970 2255 865 Extension for reply within form onth  1003 330 2002 165 Desire life fee  1003 190 2401 1600 Notice of Appeal  1004 750 2001 375 Reisse filing fee  1005 160 2003 300 Plant filing fee  1005 160 2003 300 Plant filing fee  1005 160 2003 300 1000 1000 1000 1000 1000 1000							
The Commissioner is authorized to: check all train apply 2 Charge Respi Dictated below 2 Commissioner in authorized to: check all train apply 2 Charge Respi Dictated below 2 Commissioner in 2 Charge Respi Dictated below 2 Commissioner in 2 Charge Respi Dictated below 2 Commissioner in 2 Charge Respi Dictated Dictated Distorer in 2 Charge Respi Distorer in 2 Charge Respi Dictated Distorer in 2 Charge Respi							
Charge any additional fee(s) during the pendency of this application   1812   2,520   1812   2,520   For filing an Quest for reasonalization   1815   2,520   1815   2,520   For filing an Quest for reasonalization of SIR phort   1815   1,840   1,840							
Charge Regist)   Michael of Below   Except for the filling fee to the above   1804   920*   1804   920*   1805   1,840*   1,840*   1805   1,840*							
1805   1,840°   1,840°   1,84	harge fee(s) indicated below, except for the filling fee to the above-						
1.8ASIC FILING FEE   Large Entity							
1. BASIC FILING FEE							
Large Entity   Small Entity   Small Entity   Small Entity   Fee Paid   1253   350   2253   485   Extension for reply within third month   1254   1,450   2254   225	닐						
Fee   East   E							
Code							
1002   309   2002   185   Design Hilling fee   1401   300   2401   1800   Notice of Anoese   1401   300   2401   300   Notice of Anoese   1401   300							
1033   250   2033   250   Plant fillino fee							
1004   750   2004   375   Roissue Risin fee   1403   2800   2403   140   Rousest form bearing   1451   1,510		l					
1005   160   2005   80   filing fee     1451   1,510   1451   1,510   Petition to institute a public use proceeding   1451   1,510   1451   1,510   Petition to institute a public use proceeding   1451   1,510   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1,510   1451   1,510   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1451   1,510   1,510   1451   1,510   1451   1,510   1451   1,510	-						
SUBTOTAL (1)   750   1452   110   2452   55   Petition to revive - unavoidable		1					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE  Extra Fee Hold  1501 1,300 2453 650 Peltiton to revive - unintentional  1501 1,300 2501 650 Utility issue fee (or reissue)  1501 1,300 2501 650 Utility issue fee  1502 470 2502 235 Design issue fee  1503 530 2503 355 Pinitissue fee  1504 130 1460 130 Peltitons to the Commissioner							
California   Cal	H	1					
Total Claims   20   -20"   X   = 0   1500   1600	#=	ł					
Independent 5 -3"-, 2 x 84 168 1503 630 2503 315 Plant Issue fee Claims Claims 0 = 0 1460 130 1460 130 Petitions to the Commissioner							
Claims         Auxiliary         1460         130         Petitions to the Commissioner							
Multiple Dependent 0 ≈ 0 1460 130 1460 130 Petitions to the Commissioner							
** or number acquisitely paid # greater Fox Pointure con below 1907 E0 1907 E0 Proceeding to under 27 CED 1 17		1					
	) 🔲						
Large Entity Small Entity 1801 750 2801 375 Request for Continued Examination (RCE)							
Fee Fee Code (\$) Code (\$) 1806 180 1806 180 Submission of Information Disclosure							
1202 18 2202 9 Claims in excess of 20 8021 40 8021 40 Recording each patent assignment per property (times number of							
properties) 1201 84 2201 42 Independent claims in excess of 3 1809 750 2809 375 Filing e submission after final rejecti (37 CPR 1:29(a))	-						
1203 260 2203 140 Multiple dependent claim, if not paid 1810 750 2810 375 For each additional invention to be examined (37 CFR 1.129(b))							
1204 84 2204 42 **Reissue independent claims over original patent Other Fee (specify)	be examined (37 CFR 1.129(b))  4 42 "Reissue independent claims over Other Fee (specify)						
1205 18 2205 9 "Reissue claims in excess of 20 and over original patent" "Reduced by Basic Filing Fee Paid		Reduced by Basic Filing Fee Paid					
SUBTOTAL (2) (\$) 168.00 SUBTOTAL (3) (\$) 0							

SUBMITTED BY A A					Complete (if Appli	cable)
Name (Printed/Type)	oseph R Reidy	ו וא			Reg. Number	39,340
Signature	meth -	. Blide	Date	July 17, 2003	Telephone	858-622-7320
	J7	7				

AG0073-01-US
Transmittal Letter for Divisional Application

certificate of Mailing (37 C.F.R. §1.10); I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV341079272US in an envelope addressed to:

Mail Stop: Patent Application Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 17th day of July 2003.

Group Art Unit: 1624

Examiner: HABTE, KAHSAY

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Steven Lee Bender et al.

Serial No.: Not Yet Assigned

Filed: Herewith

For: AMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR

INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE

Mail Stop: Patent Applications Honorable Commissioner for Patents Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Submitted herewith are the following documents:

Utility Patent Application Transmittal Fee Transmittal Preliminary Amendment Information Disclosure Statement

PTO Form SB.08B (1449) Combined Declaration and Power of Attorney Assignment and Cover Sheet

Specification

ClaimsAbstract

1 page:

1 page + Duplicate:

23 pages;

2 pages;

11 pages;

4 pages; 5 pages;

212 pages Total;

15 pages; and

1 page.

Respectfully Submitted.

Attorney for Applicants Red. No. 39.340

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department

10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-7320 Fax: (858) 678-8233